Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation

Journal of Immunology

Volumn 194, Issue 7, 2015, Pages 3180-3190

  Toniolo, Patricia A ^a,b,c   Liu, Suhu ^a,b   Yeh, Jennifer E ^a,b   Moraes Vieira, Pedro M ^b   Walker, Sarah R ^a,b   Vafaizadeh, Vida ^d   Barbuto, José Alexandre M ^c   Frank, David A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; CD83 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12P70; STAT5 PROTEIN; (+)-JQ1 COMPOUND; AUTACOID; AZEPINE DERIVATIVE; CYTOKINE; JANUS KINASE; MEMBRANE ANTIGEN; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; INHIBITION KINETICS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TH1 CELL; TRANSCRIPTION INITIATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; NORMAL HUMAN; PROTEIN DOMAIN; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, SURFACE; AZEPINES; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEALTHY VOLUNTEERS; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; JANUS KINASES; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; MONOCYTES; PHENOTYPE; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84925868296     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401635     Document Type: Article

References (36)

1. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
2. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449: 419-426.
3. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
4. Steinman, R. M. 2003. The control of immunity and tolerance by dendritic cell. Pathol. Biol. (Paris) 51: 59-60.
5. Van Brussel, I., W. P. Lee, M. Rombouts, A. H. Nuyts, M. Heylen, B. Y. De Winter, N. Cools, and D. M. Schrijvers. 2014. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality? Autoimmun. Rev. 13: 138-150.
6. Hansen, M., G. M. Hjortø, M. Donia, Ö. Met, N. B. Larsen, M. H. Andersen, P. thor Straten, and I. M. Svane. 2013. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine 31: 639-646.
7. Yeh, J. E., P. A. Toniolo, and D. A. Frank. 2013. Targeting transcription factors: promising new strategies for cancer therapy. Curr. Opin. Oncol. 25: 652-658.
8. Yoshimura, A. 2009. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J. Med. 58: 73-83.
9. Jackson, S. H., C. R. Yu, R. M. Mahdi, S. Ebong, and C. E. Egwuagu. 2004. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J. Immunol. 172: 2307-2315.
10. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179: 1109-1118.
11. Lutz, M. B., M. Schnare, M. Menges, S. Rössner, M. Röllinghoff, G. Schuler, and A. Gessner. 2002. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J. Immunol. 169: 3574-3580.
12. Esashi, E., Y. H. Wang, O. Perng, X. F. Qin, Y. J. Liu, and S. S. Watowich. 2008. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28: 509-520.
13. Li, H. S., C. Y. Yang, K. C. Nallaparaju, H. Zhang, Y. J. Liu, A. W. Goldrath, and S. S. Watowich. 2012. The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development. Blood 120: 4363-4373.
14. Liu, S., S. R. Walker, E. A. Nelson, R. Cerulli, M. Xiang, P. A. Toniolo, J. Qi, R. M. Stone, M. Wadleigh, J. E. Bradner, and D. A. Frank. 2014. Targeting STAT5 in hematological malignancies through inhibition of the bromodomain and extraterminal (BET) bromodomain protein BRD2. Mol. Cancer Ther. 13: 1194-1205.
15. Delmore, J. E., G. C. Issa, M. E. Lemieux, P. B. Rahl, J. Shi, H. M. Jacobs, E. Kastritis, T. Gilpatrick, R. M. Paranal, J. Qi, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
16. Filippakopoulos, P., J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
17. Ott, C. J., N. Kopp, L. Bird, R. M. Paranal, J. Qi, T. Bowman, S. J. Rodig, A. L. Kung, J. E. Bradner, and D. M. Weinstock. 2012. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120: 2843-2852.
18. Wienerroither, S., I. Rauch, F. Rosebrock, A. M. Jamieson, J. Bradner, M. Muhar, J. Zuber, M. Müller, and T. Decker. 2014. Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. Mol. Cell. Biol. 34: 415-427.
19. Belkina, A. C., B. S. Nikolajczyk, and G. V. Denis. 2013. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 190: 3670-3678.
20. O'Shea, J. J., S. M. Holland, and L. M. Staudt. 2013. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368: 161-170.
21. Nelson, E. A., S. R. Walker, J. V. Alvarez, and D. A. Frank. 2004. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J. Biol. Chem. 279: 54724-54730.
22. Vafaizadeh, V., P. Klemmt, C. Brendel, K. Weber, C. Doebele, K. Britt, M. Grez, B. Fehse, S. Desriviéres, and B. Groner. 2010. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 28: 928-938.
23. Yamaoka, K., T. Otsuka, H. Niiro, Y. Arinobu, Y. Niho, N. Hamasaki, and K. Izuhara. 1998. Activation of STAT5 by lipopolysaccharide through granulocyte-macrophage colony-stimulating factor production in human monocytes. J. Immunol. 160: 838-845.
24. Hu, J., D. Lou, B. Carow, M. E. Winerdal, M. Rottenberg, A. C. Wikström, G. Norstedt, and O. Winqvist. 2012. LPS regulates SOCS2 transcription in a type I interferon dependent autocrine-paracrine loop. PLoS ONE 7: e30166.
25. Miah, M. A., C. H. Yoon, J. Kim, J. Jang, Y. R. Seong, and Y. S. Bae. 2012. CISH is induced during DC development and regulates DC-mediated CTL activation. Eur. J. Immunol. 42: 58-68.
26. Zhang, Q., H. Y. Wang, F. Wei, X. Liu, J. C. Paterson, D. Roy, D. Mihova, A. Woetmann, A. Ptasznik, N. Odum, et al. 2014. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J. Immunol. 192: 2913-2919.
27. Zhu, J., and W. E. Paul. 2008. CD4 T cells: fates, functions, and faults. Blood 112: 1557-1569.
28. Lehtonen, A., S. Matikainen, M. Miettinen, and I. Julkunen. 2002. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J. Leukoc. Biol. 71: 511-519.
29. Cohen, P. A., G. K. Koski, B. J. Czerniecki, K. D. Bunting, X. Y. Fu, Z. Wang, W. J. Zhang, C. S. Carter, M. Awad, C. A. Distel, et al. 2008. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 112: 1832-1843.
30. Hu, J., O. Winqvist, A. Flores-Morales, A. C. Wikström, and G. Norstedt. 2009. SOCS2 influences LPS induced human monocyte-derived dendritic cell maturation. PLoS ONE 4: e7178.
31. Podojil, J. R., and S. D. Miller. 2009. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol. Rev. 229: 337-355.
32. Bell, B. D., M. Kitajima, R. P. Larson, T. A. Stoklasek, K. Dang, K. Sakamoto, K. U. Wagner, D. H. Kaplan, B. Reizis, L. Hennighausen, and S. F. Ziegler. 2013. The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. Nat. Immunol. 14: 364-371.
33. Tormo, A. J., and J. F. Gauchat. 2013. A novel role for STAT5 in DC: Controlling the Th2-response. JAK-STAT 2: e25352.
34. Aerts-Toegaert, C., C. Heirman, S. Tuyaerts, J. Corthals, J. L. Aerts, A. Bonehill, K. Thielemans, and K. Breckpot. 2007. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 37: 686-695.
35. Pinho, M. P., I. K. Migliori, E. A. Flatow, and J. A. Barbuto. 2014. Dendritic cell membrane CD83 enhances immune responses by boosting intracellular calcium release in T lymphocytes. J. Leukoc. Biol. 95: 755-762.
36. Mele, D. A., A. Salmeron, S. Ghosh, H. R. Huang, B. M. Bryant, and J. M. Lora. 2013. BET bromodomain inhibition suppresses TH17-mediated pathology. J. Exp. Med. 210: 2181-2190.